The review on: “Creutzfeldt-Jakob disease”
Article Sidebar
-
Creutzfeldt-Jakob disease (CJD), Genetic CJD, Prion, Sporadic CJD (sCJD), Transmissible spongiform encephalopathy (TSEs), Treatment
Abstract
This review will explore the information about Creutzfeldt -Jakob disease (CJD), which is the human prion disease. CJD is a rare brain disorder and rapidly progressive. CJD belongs to the family of human prion disease, which is caused by misfolded, transmissible infections particles, or prions. Transmissible spongiform encephalopathy (TSEs), also known as prion disease. Spongiform refers to the characteristic appearance of infected brains. CJD affects about one person in every one million people per year worldwide. CJD is a fatal neurodegenerative disorder which is having a higher mortality rate. CJD usually appears in later life and has a high incubation period but become rapidly progressive once clinically symptoms begin. CJD exist in three major groups sporadic CJD (sCJD), Acquired CJD, and Genetic CJD. The sporadic form generally affects the late middle age or elderly persons (Mean age of 67 years). Most people with clinically diagnosed CJD die within a year. Other neurodegenerative illness like Alzheimer's disease involves the deposition of an aberrantly folded protein: although CJD is transmissible. There is no specific treatment for CJD except for supportive care. The arrangement of different clinicians and surveillance programs can maintain awareness of CJD to control the future incidence of its transmission.
Full text article
References
Graeme Mackenzie and Robert Will. Creutzfeldt-Jakob disease: recent developments. F1000Research, 6:2053, 2017.
Yaushi lwasaki. Creutzfeldt-Jakob disease. Neuropathology, 37(2):174–188, 2017.
Diego Cardoso Fragoso, Augusto Lio da Mota Gonçalves Filho, Felipe Torres Pacheco, et al. Imaging of Creutzfeldt-Jakob Disease: Imaging Patterns and Their Differential Diagnosis. Neurologic/Head and Neck Imagine, 37(1):234– 257, 2017.
M. da mota Gomes. Creutzfeldt-Jakob disease: one hundred years of participation in the design of the transmissible spongiform encephalopathy. Rev Bras Neurol, 53(3):25– 28, 2020.
W Spielmeyer. Die histopathologische Forschung in der Psychiatrie. Klin Wochenschr, 1(37):1817–1819, 1922.
J Wadsworth, S Joiner, A Hill, et al. Tissue distribution of protease-resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. The Lancet, 358(9277):171–180, 2001.
G Robert Will. Acquired prion disease: iatro- genic CJD, variant CJD, kuru. Br. Med. Bull., 66:255–265, 2003.
MW Head. Human prion diseases: molecular, cellular and population biology. Neuropathology, 33(3):221–236, 2013.
L Uttley, R Wong, C Carroll, et al. Creutzfeldt- Jakob disease: a systematic review of Global incidence, prevalence, infectivity, and incubation. The Lancet Infectious Diseases, 20(1):E2– E10, 2020.
Y C Liao, R V Lebo, G A Clawson, and E A Smuckler. Human prion protein cDNA: molecular cloning, chromosomal mapping, and biological implications. Science, 233(4761):364–367, 1986.
Jean Y. Douet, Caroline Lacroux, Naima Aron, et al. Distribution and Quantitative Estimates of Variant Creutzfeldt-Jakob Disease Prions in Tissues of Clinical And Asymptomatic Patients. Emerging Infectious Diseases, 23(6):946–956, 2017.
S B Prusiner. Prions. Proc Natl Acad Sci U S A, 95:13363–13383, 1998.
J C Abrahantes, M Aerts, et al. Classification of sporadic Creutzfeldt-Jakob disease based on clinical and neuropathological characteristics. European Journal of Epidemiology, 22(7):457– 465, 2007.
A Ladogana, M Puopolo, E A Croes, et al. Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. Neurology, 64(9):1586–1591, 2005.
Piero Parchi and Daniela Saverioni. Molecular pathology, classification, and diagnosis of sporadic human prion disease variants. Folia Neuropathol., 50(1):20–45, 2012.
Ignazio cali, Gianfreanco pouti, Jason smucny, Paul Micharl curtiss, et al. Co-existence of PrPD types 1 and 2 in sporadic Creutzfeldt- Jakob disease of the VV subgroup: phenotypic and prion protein characteristic. Scientific Reports, 10(1):1503, 2020.
Pierluigi Gambetti, Qingzhong Kong, Wenquan Zou, Piero Parchi, and G Shu Chen. Sporadic and familial CJD: classification and characterisation. British medical bulletin, 66(1):213– 239, 2003.
R Wada and W Kucharczyk. Prion infections of the brain. Neuroimaging Clin N am , 18(1):183– 191, 2008.
Neil Watson, Jean-Philippe, Brandel, Alison Green, Peter Hermann, Anna Ladogana, Terri Lindsay, Janet Mackenzie, Maurizio Pocchiari, Colin Smith, Inga Zerr, and Suvankar Pal. The importance of ongoing surveillance for Creutzfeldt-Jakob disease. Nature reviews, Neurology, 17(6):362–379, 2021.
James W. Ironside. Variant Creutzfeldt- Jakob disease: an update. Folia Neuropathol, 50(1):50–56, 2012. University of Edinburgh, western general hospital.
Richard Knight. Creutzfeldt-Jakob disease: A rare cause of dementia in elderly persons. Clin Infect Dis., 43(3):340–346, 2006. National Creutzfeldt-Jakob disease surveillance Unit, Edinburgh, United Kingdom.
R Ae et al. Update: Dura mater graft-associated Creutzfeldt-Jakob disease - Japan, 1975-2017. MMWR Morb. Mortal Wkly Rep., 67(9):274– 278, 2018.
P Brown, M Preece, J P Brandel, et al. Iatro- genic Creutzfeldt-Jakob disease at the millennium. Neurology, 55(8):1075–1081, 2000.
Richard P Conti and Jacqueline M Arnone. Neuropsychiatric symptoms among the major categories of Creutzfeldt-Jakob Disease. International Journal of Psychiatry in Clinical Practice, 4(1):1–7, 2016.
L Monari, S C Chen, P Brown, et al. Fatal familial insomnia and familial Creutzfeldt-Jakob disease: different prion proteins determined by DNA polymorphism. Proc Natl Acad Sci USA, 91(7):2839–2842, 1994.
H G Wieser, U Schwarz, T Blättler, C Bernoulli, M Sitzler, and K Stoeck. Serial EEG findings in sporadic and iatrogenic Creutzfeldt-Jakob disease. Clin Neurophysiol, 115(11):2467–2478, 2004.
I Zerr, W J Schulz-Schaeffer, A Giese, M Bode- mer, A Schröter, and K Henkel. Current clinical diagnosis in Creutzfeldt-Jakob disease: identification of uncommon variants. Ann Neurol, 48(3):323–329, 2000.
F Caobelli, M Cobelli, C Pizzocaro, M Pavia, S Magnaldi, and U P Guerra. The role of neuroimaging in evaluating patients affected by Creutzfeldt-Jakob disease: a systematic review of the literature. J Neuroimaging, 25(1):2–13, 2015.
Aje Green, E J Thompson, and G E Stewart. Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt- Jakob disease. J Neurol Neurosurg Psychiatry, 70(6):744–748, 2001.
Marc Manix, Piyush Kalakoti, Miriam Henry, Jai Thakur, Richard Menger, Bharat Guthikonda, and Anil Nanda. Creutzfeldt-Jakob disease: Updated diagnostic criteria, treatment algorithm, and the utility of brain biopsy. Neurosurg Focus, 39(5):E2, 2015.
K K Sitammagari and W Masood. Creutzfeldt- Jakob disease. 2020. StatPearls Publishing. Update on March 6, 2021.
D Dormont. How to limit the spread of Creutzfeldt-Jakob disease. Infection control and hospital epidemiology, 17(8):521–528, 1996.
Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Article Details
